ABSTRACT

Leprosy is a chronic, treatable, disease caused by Mycobacterium leprae. Modern leprosy therapy typically consists of combinations of dapsone and rifampin with or without clofazimine depending on paubacillary or multibacillary status. The vaccine most commonly associated with leprosy prophylaxis is the BCG vaccine. The newly emerging Mycobacterium indicuspranii vaccine is also gaining prominence as a potential method of prevention however its efficacy is lesser than that of BCG. Effort is being made to develop a vaccine specific for leprosy using bio informatic tools to identify genes from M. leprae. Additionally vitamin D supplementation has also proven to be a possible treatment pathway for leprosy. Prognostic and early diagnostic tools to accompany therapeutic strategies are also under development. It has been proved that ML0405 and ML2331 are antigens of Mycobacterium leprae with potential although its use in a clinical setting is doubtful. In spite of all this the current most effective tool against leprosy is contact tracing and post exposure prophylaxis. Bed aquiline is found more effective against mycobacteria and could be considered for this article. Keywords: Leprosy, Mycobacterium leprae, dapsone and rifampin
Publication date: 01/09/2021

https://ijbpas.com/pdf/2021/September/MS_IJBPAS_2021_5630.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.9.5630